Aktis Oncology, Inc. AKTS
Nov 3, 2026, 3:27 PM EST
- YTD
- -34.51%
- 1 year
- -34.51%
- Market cap
- 815.94M
- Revenue (ttm)
- 10.06M
- EPS (ttm)
- -1.70
- Shares out
- 53.75M
- Forward P/E
- -8.45
- YTD return
- -34.51%
- 1-year return
- -34.51%
- Volume
- 315.10K
- Avg volume
- 370.60K
- Open
- 14.76
- Previous close
- 14.59
- Day's range
- 14.40 – 15.09
- 52-week range
- 13.96 – 34.19
- Analysts
- Strong Buy
- Price target
- 35.39 (+141.2%)
- Earnings date
- Nov 12, 2026
1m -1.46 (-9.19%)
Key statistics
- Enterprise value
- 495.07M
- PEG ratio
- 0.00
- Price / sales
- 100.35
- Price / book
- 2.07
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 111.40%
- Free cash flow
- 0
- Total cash
- 517.32M
- Total debt
- 11.24M
- Return on equity
- 0.00%
- Short % of float
- 20.12%
- 50-day average
- 22.96
- 200-day average
- 21.42
Analyst view
Consensus: strong buy
- Target (low)
- 31.50
- Target (mean)
- 35.39
- Target (high)
- 40.00
- Strong buy1
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.45803.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.47 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | -0.43065 | -0.44 | -0.01 | -2.17% |
| May 11, 2026 | Mar 31, 2026 | -0.31 | -0.38 | -0.07 | -22.58% |
| Mar 30, 2026 | Dec 31, 2025 | -21.59 | -18.19 | +3.40 | +15.76% |
| Dec 3, 2025 | Sep 30, 2025 | -0.11 | -1.39 | -1.28 | -1,163.64% |
| Nov 14, 2024 | Sep 30, 2024 | -0.10 | -0.04 | +0.06 | +60.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 2026 | Wedbush | reit | Outperform | Outperform |
| Sep 9, 2026 | Oppenheimer | init | — | Outperform |
| Aug 19, 2026 | Wedbush | init | — | Outperform |
| Aug 19, 2026 | BMO Capital | init | — | Outperform |
| Jul 14, 2026 | JP Morgan | main | Overweight | Overweight |
| Jun 16, 2026 | Raymond James | init | — | Strong Buy |
About Aktis Oncology, Inc.
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aktisoncology.com
News
Aktis Oncology: Padcev Is Building The Market It Wants 
Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target 
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519 
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3 
Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript - Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40
Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35 
BMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37 
Bank of America Sees Bargains in These 16 Knocked-Down AI Stocks 
Micron and 15 Other Stocks To Play The AI Buildout Race: They Are Still 20% Below Highs
Your note
Sign in to keep a note on AKTS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CZIBERE AKOS M.D. | Officer | Sale | Sep 22, 2026 | 0 |
| ECOR1 CAPITAL, L.L.C. | Unknown | Purchase | Jan 11, 2026 | 0 |
| FOLEY TODD | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 11, 2026 | 0 |
| GADICKE ANSBERT S. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 11, 2026 | 0 |
| HERRMANN KEN M.D. | Director | Sale | Jul 19, 2026 | 0 |
| KIM HELEN SUSAN | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 11, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MPM Bioimpact LLC | 9.00% | 4,835,872 | 87.77M | Jun 29, 2026 |
| EcoR1 Capital, LLC | 8.98% | 4,824,469 | 87.56M | Jun 29, 2026 |
| Blue Owl Capital Holdings LP | 5.71% | 3,070,219 | 55.72M | Jun 29, 2026 |
| Blackrock Inc. | 4.24% | 2,278,358 | 41.35M | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 3.82% | 2,051,447 | 37.23M | Jun 29, 2026 |
| Wellington Management Group, LLP | 3.66% | 1,966,244 | 35.69M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.72% | 1,462,244 | 26.54M | Jul 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 1.26% | 676,577 | 12.28M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.09% | 585,135 | 10.62M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.01% | 542,593 | 9.85M | Aug 30, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 0.94% | 507,000 | 9.20M | Jun 29, 2026 |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 0.67% | 358,947 | 6.51M | Jun 29, 2026 |